Benefit from b-lymphocyte depletion using the anti-CD20 antibody rituximab in chronic fatigue syndrome. a double-blind and placebo-controlled study

PLoS ONE

Volumn 6, Issue 10, 2011, Pages

  Fluge, Øystein ^a   Bruland, Ove ^a   Risa, Kristin ^a   Storstein, Anette ^a   Kristoffersen, Einar K ^a   Sapkota, Dipak ^a   Næss, Halvor ^a   Dahl, Olav ^a,b   Nyland, Harald ^a   Mella, Olav ^a,b  

^a HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF BERGEN   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

CD20 ANTIBODY; PLACEBO; RITUXIMAB; SODIUM CHLORIDE; CD20 ANTIGEN; MONOCLONAL ANTIBODY;

ABDOMINAL PAIN; ACNE; ADULT; ARTICLE; B LYMPHOCYTE; BALANITIS; CHRONIC FATIGUE SYNDROME; CLINICAL ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG RESPONSE; FEMALE; FOLLOW UP; GENOTYPE; HEART PALPITATION; HUMAN; IMMUNOPHENOTYPING; INJECTION SITE DISCOMFORT; INSOMNIA; LOW BACK PAIN; LYMPHOCYTE DEPLETION; LYMPHOCYTE SUBPOPULATION; MALE; MENSTRUAL IRREGULARITY; NAUSEA; PHASE 2 CLINICAL TRIAL; PRURITUS; PSORIASIS; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SELF REPORT; SHORT FORM 36; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VIRUS DETECTION; XENOTROPIC MULV RELATED VIRUS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; IMMUNOLOGY; MIDDLE AGED; POLYMERASE CHAIN REACTION; TREATMENT OUTCOME;

XENOTROPIC MURINE LEUKEMIA VIRUS;

ADULT; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIGENS, CD20; B-LYMPHOCYTES; DOUBLE-BLIND METHOD; FATIGUE SYNDROME, CHRONIC; FEMALE; HUMANS; LYMPHOCYTE DEPLETION; MALE; MIDDLE AGED; PLACEBOS; POLYMERASE CHAIN REACTION; TREATMENT OUTCOME;

EID: 80054793227     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0026358     Document Type: Article

References (30)

1. Devanur LD, Kerr JR, (2006) Chronic fatigue syndrome. J Clin Virol 37: 139-150.
2. Capelli E, Zola R, Lorusso L, Venturini L, Sardi F, et al. (2010) Chronic fatigue syndrome/myalgic encephalomyelitis: an update. Int J Immunopathol Pharmacol 23: 981-989.
3. Nacul LC, Lacerda EM, Pheby D, Campion P, Molokhia M, et al. (2011) Prevalence of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) in three regions of England: a repeated cross-sectional study in primary care. BMC Med 9: 91.
4. Fluge O, Mella O, (2009) Clinical impact of B-cell depletion with the anti-CD20 antibody rituximab in chronic fatigue syndrome: a preliminary case series. BMC Neurol 9: 28.
5. Fukuda K, Straus SE, Hickie I, Sharpe MC, Dobbins JG, et al. (1994) The chronic fatigue syndrome: a comprehensive approach to its definition and study. International Chronic Fatigue Syndrome Study Group. Ann Intern Med 121: 953-959.
6. Blacker CV, Greenwood DT, Wesnes KA, Wilson R, Woodward C, et al. (2004) Effect of galantamine hydrobromide in chronic fatigue syndrome: a randomized controlled trial. Jama 292: 1195-1204.
7. Naess H, Sundal E, Myhr KM, Nyland HI, (2010) Postinfectious and chronic fatigue syndromes: clinical experience from a tertiary-referral centre in Norway. In Vivo 24: 185-188.
8. Carruthers BM, Jain AK, De Meirleir KL, Peterson DL, Klimas NG, et al. (2003) Myalgic encephalomyelitis/chronic fatigue syndrome: clinical working case definition, diagnostic and treatment protocols. J Chronic Fatigue Syndr 11: 7-36.
9. Sanz I, Lee FE, (2010) B cells as therapeutic targets in SLE. Nat Rev Rheumatol 6: 326-337.
10. Ortega-Hernandez OD, Shoenfeld Y, (2009) Infection, vaccination, and autoantibodies in chronic fatigue syndrome, cause or coincidence? Ann N Y Acad Sci 1173: 600-609.
11. Blank M, Barzilai O, Shoenfeld Y, (2007) Molecular mimicry and auto-immunity. Clin Rev Allergy Immunol 32: 111-118.
12. Broderick G, Fuite J, Kreitz A, Vernon SD, Klimas N, et al. (2010) A formal analysis of cytokine networks in chronic fatigue syndrome. Brain Behav Immun 24: 1209-1217.
13. Skowera A, Cleare A, Blair D, Bevis L, Wessely SC, et al. (2004) High levels of type 2 cytokine-producing cells in chronic fatigue syndrome. Clin Exp Immunol 135: 294-302.
14. Aspler AL, Bolshin C, Vernon SD, Broderick G, (2008) Evidence of inflammatory immune signaling in chronic fatigue syndrome: A pilot study of gene expression in peripheral blood. Behav Brain Funct 4: 44.
15. Townsend MJ, Monroe JG, Chan AC, (2010) B-cell targeted therapies in human autoimmune diseases: an updated perspective. Immunol Rev 237: 264-283.
16. Kessel A, Rosner I, Toubi E, (2008) Rituximab: beyond simple B cell depletion. Clin Rev Allergy Immunol 34: 74-79.
17. Rizzi M, Knoth R, Hampe CS, Lorenz P, Gougeon ML, et al. (2010) Long-lived plasma cells and memory B cells produce pathogenic anti-GAD65 autoantibodies in Stiff Person Syndrome. PLoS One 5: e10838.
18. Lerner AM, Beqai S, Fitzgerald JT, Gill K, Gill C, et al. (2010) Subset-directed antiviral treatment of 142 herpesvirus patients with chronic fatigue syndrome. Virus adaptation and treatment 2: 47-57.
19. Kogelnik AM, Loomis K, Hoegh-Petersen M, Rosso F, Hischier C, et al. (2006) Use of valganciclovir in patients with elevated antibody titers against Human Herpesvirus-6 (HHV-6) and Epstein-Barr Virus (EBV) who were experiencing central nervous system dysfunction including long-standing fatigue. J Clin Virol 37 (Suppl 1): S33-38.
20. Pace TW, Heim CM, (2011) A short review on the psychoneuroimmunology of posttraumatic stress disorder: from risk factors to medical comorbidities. Brain Behav Immun 25: 6-13.
21. Gurcan HM, Keskin DB, Stern JN, Nitzberg MA, Shekhani H, et al. (2009) A review of the current use of rituximab in autoimmune diseases. Int Immunopharmacol 9: 10-25.
22. Covelli M, Sarzi-Puttini P, Atzeni F, Macchioni P, (2010) Safety of rituximab in rheumatoid arthritis. Reumatismo 62: 101-106.
23. Cooper N, Arnold DM, (2010) The effect of rituximab on humoral and cell mediated immunity and infection in the treatment of autoimmune diseases. Br J Haematol 149: 3-13.
24. Carson KR, Evens AM, Richey EA, Habermann TM, Focosi D, et al. (2009) Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood 113: 4834-4840.
25. Lombardi VC, Ruscetti FW, Das Gupta J, Pfost MA, Hagen KS, et al. (2009) Detection of an Infectious Retrovirus, XMRV, in Blood Cells of Patients with Chronic Fatigue Syndrome. Science 326: 585-589.
26. Lo SC, Pripuzova N, Li B, Komaroff AL, Hung GC, et al. (2010) Detection of MLV-related virus gene sequences in blood of patients with chronic fatigue syndrome and healthy blood donors. Proc Natl Acad Sci U S A 107: 15874-15879.
27. Satterfield BC, Garcia RA, Jia H, Tang S, Zheng H, et al. (2011) Serologic and PCR testing of persons with chronic fatigue syndrome in the United States shows no association with xenotropic or polytropic murine leukemia virus-related viruses. Retrovirology 8: 12.
28. Shin CH, Bateman L, Schlaberg R, Bunker AM, Leonard CJ, et al. (2011) Absence of XMRV Retrovirus and Other Murine Leukemia Virus-Related Viruses in Patients with Chronic Fatigue Syndrome. J Virol 85: 7195-7202.
29. Paprotka T, Delviks-Frankenberry KA, Cingoz O, Martinez A, Kung HJ, et al. (2011) Recombinant origin of the retrovirus XMRV. Science 333: 97-101.
30. Knox K, Carrigan D, Simmons G, Teque F, Zhou Y, et al. (2011) No evidence of murine-like gammaretroviruses in CFS patients previously identified as XMRV-infected. Science 333: 94-97.